Biomarker hub
IDH1 mutation
Trials and papers mentioning IDH1 mutation.
Trials mentioning idh1View all trials
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
RECRUITING · Phase not listed
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
ACTIVE_NOT_RECRUITING · Phase not listed
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
COMPLETED · Phase not listed
Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
TERMINATED · Phase not listed
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
ACTIVE_NOT_RECRUITING · Phase not listed
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
RECRUITING · Phase not listed
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
RECRUITING · Phase not listed
MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma
RECRUITING · Phase not listed
Newly Diagnosed Glioblastoma
ACTIVE_NOT_RECRUITING · Phase not listed
A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients
ACTIVE_NOT_RECRUITING · Phase not listed
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
RECRUITING · Phase not listed
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
ACTIVE_NOT_RECRUITING · Phase not listed
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
ACTIVE_NOT_RECRUITING · Phase not listed
A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
ACTIVE_NOT_RECRUITING · Phase not listed
Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
RECRUITING · Phase not listed
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
ACTIVE_NOT_RECRUITING · Phase not listed
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
RECRUITING · Phase not listed
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors
ACTIVE_NOT_RECRUITING · Phase not listed
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RECRUITING · Phase not listed
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
RECRUITING · Phase not listed
Papers mentioning idh1View all papers
No papers found yet for idh1. Try the broader papers search.